[go: up one dir, main page]

MX2019004973A - Moduladores de ror gamma. - Google Patents

Moduladores de ror gamma.

Info

Publication number
MX2019004973A
MX2019004973A MX2019004973A MX2019004973A MX2019004973A MX 2019004973 A MX2019004973 A MX 2019004973A MX 2019004973 A MX2019004973 A MX 2019004973A MX 2019004973 A MX2019004973 A MX 2019004973A MX 2019004973 A MX2019004973 A MX 2019004973A
Authority
MX
Mexico
Prior art keywords
modulators
ror
ror gamma
gamma modulators
disorders
Prior art date
Application number
MX2019004973A
Other languages
English (en)
Other versions
MX392163B (es
Inventor
Harris Jason
Mohan Raju
Nuss John
Original Assignee
Escalier Biosciences Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Escalier Biosciences Bv filed Critical Escalier Biosciences Bv
Publication of MX2019004973A publication Critical patent/MX2019004973A/es
Publication of MX392163B publication Critical patent/MX392163B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Processing Of Color Television Signals (AREA)
  • Picture Signal Circuits (AREA)
  • Details Of Television Scanning (AREA)

Abstract

En el presente documento se describen moduladores del receptor nuclear huérfano (ROR), relacionados con el ácido retinoico y métodos para utilizar los moduladores del ROR? en el tratamiento de enfermedades, trastornos o afecciones dérmicas. En el presente documento también se describen composiciones farmacéuticas que contienen tales compuestos.
MX2019004973A 2016-10-27 2017-10-27 Moduladores de ror gamma. MX392163B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662413907P 2016-10-27 2016-10-27
PCT/US2017/058755 WO2018081558A1 (en) 2016-10-27 2017-10-27 Ror-gamma modulators

Publications (2)

Publication Number Publication Date
MX2019004973A true MX2019004973A (es) 2019-09-19
MX392163B MX392163B (es) 2025-03-21

Family

ID=62024021

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004973A MX392163B (es) 2016-10-27 2017-10-27 Moduladores de ror gamma.

Country Status (14)

Country Link
US (5) US10905687B2 (es)
EP (1) EP3532062B1 (es)
JP (1) JP7027437B2 (es)
KR (1) KR102598775B1 (es)
CN (1) CN110139652B (es)
AU (1) AU2017348345B2 (es)
BR (1) BR112019008548A2 (es)
CA (1) CA3042080A1 (es)
ES (1) ES2928904T3 (es)
IL (1) IL266261B (es)
MX (1) MX392163B (es)
PH (1) PH12019500949A1 (es)
RU (1) RU2753490C2 (es)
WO (1) WO2018081558A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019008548A2 (pt) 2016-10-27 2019-09-17 Escalier Biosciences Bv moduladores ror-gama
JP2021517563A (ja) 2018-03-12 2021-07-26 エスカリア バイオサイエンシーズ，ビーブイ 二環式ＲＯＲγモジュレーター
US11242350B2 (en) 2018-03-12 2022-02-08 Escalier Biosciences B.V. Spirocyclic ROR-gamma modulators
BR112022008607A2 (pt) * 2019-11-05 2022-08-09 Dermira Inc Inibidores de ror gama t e usos tópicos dos mesmos
JP2023540665A (ja) * 2020-06-30 2023-09-26 デルミラ インコーポレイテッド ＲＯＲγＴ阻害剤及びそれらの局所使用
CN111892599B (zh) * 2020-08-14 2023-01-13 黄芳 一种2,5-二氮杂双环[2.2.2]辛烷-2-羧酸叔丁酯的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432957B1 (en) 2001-06-29 2002-08-13 Kowa Co., Ltd. Piperazine derivative
AU2003280558A1 (en) 2002-10-11 2004-05-04 Kowa Co., Ltd. Method for treatment of cancer
TW201006816A (en) 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
HUP1100166A2 (en) * 2011-03-29 2012-12-28 Sanofi Sa Reductive amination process for preparation of dronedarone using amine intermediary compound
WO2012158784A2 (en) * 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
NO2758060T3 (es) * 2011-09-19 2018-04-28
AR092348A1 (es) * 2012-07-11 2015-04-15 Hoffmann La Roche DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc
EP3268087A4 (en) * 2015-03-12 2018-08-29 The Regents of the University of California METHODS FOR TREATING CANCER WITH RORgamma INHIBITORS
BR112019008548A2 (pt) 2016-10-27 2019-09-17 Escalier Biosciences Bv moduladores ror-gama

Also Published As

Publication number Publication date
WO2018081558A1 (en) 2018-05-03
US10905687B2 (en) 2021-02-02
EP3532062A4 (en) 2020-04-15
MX392163B (es) 2025-03-21
AU2017348345A1 (en) 2019-05-30
ES2928904T3 (es) 2022-11-23
US20190269674A1 (en) 2019-09-05
US20210069182A1 (en) 2021-03-11
CN110139652B (zh) 2022-10-11
RU2019115059A3 (es) 2020-12-18
RU2753490C2 (ru) 2021-08-17
IL266261B (en) 2022-07-01
KR102598775B1 (ko) 2023-11-03
US20230277527A1 (en) 2023-09-07
JP2019535813A (ja) 2019-12-12
JP7027437B2 (ja) 2022-03-01
CN110139652A (zh) 2019-08-16
KR20190096979A (ko) 2019-08-20
US20240216361A1 (en) 2024-07-04
IL266261A (en) 2019-06-30
CA3042080A1 (en) 2018-05-03
BR112019008548A2 (pt) 2019-09-17
EP3532062B1 (en) 2022-07-20
EP3532062A1 (en) 2019-09-04
PH12019500949A1 (en) 2019-08-05
AU2017348345B2 (en) 2022-01-27
RU2019115059A (ru) 2020-11-27
US20220175765A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
MX2019004973A (es) Moduladores de ror gamma.
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2016001364A1 (es) Moduladores de ror gamma (rory)
MX2021009561A (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma.
MX2021009673A (es) Moduladores de ror-gamma.
MX2017014375A (es) Moduladores del ccr2.
ECSP21016032A (es) Inhibidores de la interacción proteína-proteína keap1-nrf2
MX2016015630A (es) Nuevos compuestos.
UY37098A (es) Moduladores de ror-gamma
CL2020001990A1 (es) Moduladores del receptor nmda espiro-lactama y usos de los mismos. (hna. 1991-20)
MX2020008107A (es) Moduladores del receptor nmda espiro-lactama y usos de los mismos.
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CL2018002335A1 (es) Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1
MX2016010998A (es) Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
CL2017002799A1 (es) Sulfonas triciclicas como moduladores del receptor huérfano relacionado con retinoide gamma (rory)
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
CR20170108A (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos
MX2017000183A (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
GT201700194A (es) Formulación de combinación de tesofensina y betabloqueante
CO2020005485A2 (es) Administración oral de análogos del péptido glp-1
PH12016502331A1 (en) Novel compounds